.With antibiotic resistance on the rise, scientists are looking for innovative ways to combat bacterial infections. The pathogen that causes conditions from strep throat to flesh-eating disease is among them, but scientists have now found a tool that could help them fight it: a drug approved to treat HIV. Their work, appearing in the journal ACS Chemical Biology, could someday lead to new treatments.
Streptococcus is a very letahl infection which may cause simple thraot pain to skin infections but often not cured as antibiotics killing are more often resistant.As immunity change over it may cause Rheumatic fever a joint disorder leading to ValvularHeart disease a long term prophylaxsis with pencillinor other antibiotics for reinfection of streptococcus or may lead to acute or chronic kidney disease as glomerulo nephritis.If severe this bacteria may damage our muscles as flesh eating bacteria and can lead to gas gagrene or severe bacterimia or septicaemia and ultimately toxemia and death due to uncotrolled infection as drugs killing such bacteria is often resistant and scietist are on the process of exploring the good medicine.
BUT THIS STUDY HAS SHOWN US A LIFE BREAKING RESEARCH WHERE A PROTEASE INHIBITOR GROUP HIV ART DRUG "NELFINAVIR' CAN CHECK THIS BACTERIA .

Douglas A. Mitchell and colleagues point out that Streptococcus pyogenes is responsible for more than 600 million illnesses and 500,000 deaths globally every year. A major factor in the pathogen's ability to cause disease is its production of a toxin called streptolysin S, or SLS. If scientists could figure out a way to jam the bacterial machinery that makes the compound, they could develop new therapies to fight the pathogen and slow the spread of antibiotic resistance. But not much is known about how S. pyogenes makes SLS. Mitchell's team wanted to start filling in the blanks.
The researchers turned to an HIV drug called nelfinavir. Although the drug's target is an HIV protein, it is also known to incidentally block a key enzyme in patients. That enzyme is related to one in S. pyogenes that is critical for producing SLS. The scientists made several nelfinavir-like compounds that stopped the bacteria from making the toxin in lab tests. They conclude that the drug and its variants could help future efforts to understand how the deadly bacteria works and how to stop it.